Autolus Property Plant And Equipment Net vs Retained Earnings Analysis

AUTL Stock

USD 4.39 0.32 7.86%

Autolus Therapeutics financial indicator trend analysis is way more than just evaluating Autolus Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Autolus Therapeutics is a good investment. Please check the relationship between Autolus Therapeutics Property Plant And Equipment Net and its Retained Earnings accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.

Property Plant And Equipment Net vs Retained Earnings

Property Plant And Equipment Net vs Retained Earnings Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Autolus Therapeutics Property Plant And Equipment Net account and Retained Earnings. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Autolus Therapeutics' Property Plant And Equipment Net and Retained Earnings is -0.58. Overlapping area represents the amount of variation of Property Plant And Equipment Net that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Autolus Therapeutics, assuming nothing else is changed. The correlation between historical values of Autolus Therapeutics' Property Plant And Equipment Net and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Property Plant And Equipment Net of Autolus Therapeutics are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Property Plant And Equipment Net i.e., Autolus Therapeutics' Property Plant And Equipment Net and Retained Earnings go up and down completely randomly.

Correlation Coefficient

-0.58

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Most indicators from Autolus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Autolus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.Enterprise Value is expected to rise to about 882.2 M this year, although the value of Selling General Administrative will most likely fall to about 7.2 M.

	2021	2022	2024 (projected)
Depreciation And Amortization	7.4M	6.6M	4.9M
Interest Income	1.7M	11.9M	627K

Depreciation And Amortization Interest Income

Autolus Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Net Receivables	Other Current Assets	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Other Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Stockholder Equity
Total Assets		0.62	0.95	0.9	0.94	-0.78	0.01	0.98	0.94	0.35	0.76	0.99	-0.81	0.89	0.77	0.66	0.66	0.73	-0.94	0.76	-0.07	0.98	0.63	0.63	0.9	0.76
Other Current Liab	0.62		0.72	0.3	0.46	-0.74	-0.01	0.59	0.52	0.36	0.89	0.59	-0.34	0.86	0.23	0.28	0.49	0.32	-0.59	0.34	-0.2	0.59	0.4	0.45	0.43	0.74
Total Current Liabilities	0.95	0.72		0.75	0.83	-0.88	-0.12	0.88	0.96	0.55	0.87	0.9	-0.84	0.95	0.78	0.74	0.64	0.79	-0.81	0.8	-0.1	0.88	0.66	0.68	0.83	0.81
Total Stockholder Equity	0.9	0.3	0.75		0.96	-0.47	0.19	0.94	0.81	0.11	0.42	0.93	-0.72	0.61	0.75	0.56	0.58	0.64	-0.91	0.67	-0.03	0.93	0.5	0.48	0.91	0.48
Net Tangible Assets	0.94	0.46	0.83	0.96		-0.57	0.23	0.96	0.83	0.24	0.56	0.96	-0.73	0.72	0.69	0.65	0.49	0.71	-0.92	0.74	-0.17	0.95	0.62	0.59	0.97	0.55
Retained Earnings	-0.78	-0.74	-0.88	-0.47	-0.57		0.43	-0.68	-0.83	-0.58	-0.96	-0.72	0.72	-0.93	-0.6	-0.54	-0.6	-0.58	0.63	-0.58	-0.09	-0.68	-0.49	-0.53	-0.54	-0.93
Accounts Payable	0.01	-0.01	-0.12	0.19	0.23	0.43		0.07	-0.14	-0.09	-0.25	0.05	0.36	-0.2	-0.06	-0.17	-0.18	-0.16	-0.1	-0.11	-0.29	0.05	-0.13	-0.19	0.25	-0.24
Cash	0.98	0.59	0.88	0.94	0.96	-0.68	0.07		0.86	0.17	0.67	1.0	-0.75	0.83	0.68	0.59	0.64	0.67	-0.98	0.69	-0.12	1.0	0.6	0.61	0.9	0.66
Net Receivables	0.94	0.52	0.96	0.81	0.83	-0.83	-0.14	0.86		0.56	0.77	0.89	-0.86	0.86	0.91	0.74	0.67	0.79	-0.79	0.8	0.07	0.86	0.59	0.6	0.83	0.79
Other Current Assets	0.35	0.36	0.55	0.11	0.24	-0.58	-0.09	0.17	0.56		0.59	0.22	-0.4	0.46	0.55	0.52	0.13	0.47	-0.03	0.48	0.17	0.15	0.23	0.23	0.35	0.54
Total Liab	0.76	0.89	0.87	0.42	0.56	-0.96	-0.25	0.67	0.77	0.59		0.69	-0.61	0.95	0.5	0.48	0.56	0.52	-0.63	0.53	-0.03	0.67	0.48	0.52	0.54	0.92
Total Current Assets	0.99	0.59	0.9	0.93	0.96	-0.72	0.05	1.0	0.89	0.22	0.69		-0.77	0.85	0.72	0.61	0.66	0.69	-0.97	0.71	-0.09	1.0	0.61	0.61	0.9	0.69
Intangible Assets	-0.81	-0.34	-0.84	-0.72	-0.73	0.72	0.36	-0.75	-0.86	-0.4	-0.61	-0.77		-0.72	-0.73	-0.86	-0.45	-0.89	0.66	-0.89	0.15	-0.77	-0.73	-0.74	-0.77	-0.53
Common Stock	0.89	0.86	0.95	0.61	0.72	-0.93	-0.2	0.83	0.86	0.46	0.95	0.85	-0.72		0.6	0.59	0.65	0.65	-0.79	0.66	-0.09	0.83	0.62	0.65	0.68	0.87
Property Plant Equipment	0.77	0.23	0.78	0.75	0.69	-0.6	-0.06	0.68	0.91	0.55	0.5	0.72	-0.73	0.6		0.64	0.71	0.66	-0.6	0.68	0.29	0.67	0.37	0.38	0.7	0.62
Short Long Term Debt Total	0.66	0.28	0.74	0.56	0.65	-0.54	-0.17	0.59	0.74	0.52	0.48	0.61	-0.86	0.59	0.64		0.17	0.99	-0.45	0.99	-0.31	0.59	0.89	0.88	0.75	0.31
Other Liab	0.66	0.49	0.64	0.58	0.49	-0.6	-0.18	0.64	0.67	0.13	0.56	0.66	-0.45	0.65	0.71	0.17		0.24	-0.67	0.26	0.39	0.64	0.1	0.17	0.39	0.71
Property Plant And Equipment Net	0.73	0.32	0.79	0.64	0.71	-0.58	-0.16	0.67	0.79	0.47	0.52	0.69	-0.89	0.65	0.66	0.99	0.24		-0.54	1.0	-0.32	0.68	0.91	0.9	0.8	0.37
Net Debt	-0.94	-0.59	-0.81	-0.91	-0.92	0.63	-0.1	-0.98	-0.79	-0.03	-0.63	-0.97	0.66	-0.79	-0.6	-0.45	-0.67	-0.54		-0.57	0.09	-0.98	-0.51	-0.52	-0.83	-0.65
Non Current Assets Total	0.76	0.34	0.8	0.67	0.74	-0.58	-0.11	0.69	0.8	0.48	0.53	0.71	-0.89	0.66	0.68	0.99	0.26	1.0	-0.57		-0.32	0.7	0.91	0.89	0.82	0.38
Non Currrent Assets Other	-0.07	-0.2	-0.1	-0.03	-0.17	-0.09	-0.29	-0.12	0.07	0.17	-0.03	-0.09	0.15	-0.09	0.29	-0.31	0.39	-0.32	0.09	-0.32		-0.13	-0.51	-0.46	-0.26	0.28
Cash And Short Term Investments	0.98	0.59	0.88	0.93	0.95	-0.68	0.05	1.0	0.86	0.15	0.67	1.0	-0.77	0.83	0.67	0.59	0.64	0.68	-0.98	0.7	-0.13		0.62	0.63	0.89	0.66
Common Stock Shares Outstanding	0.63	0.4	0.66	0.5	0.62	-0.49	-0.13	0.6	0.59	0.23	0.48	0.61	-0.73	0.62	0.37	0.89	0.1	0.91	-0.51	0.91	-0.51	0.62		0.99	0.68	0.26
Non Current Liabilities Total	0.63	0.45	0.68	0.48	0.59	-0.53	-0.19	0.61	0.6	0.23	0.52	0.61	-0.74	0.65	0.38	0.88	0.17	0.9	-0.52	0.89	-0.46	0.63	0.99		0.65	0.31
Capital Surpluse	0.9	0.43	0.83	0.91	0.97	-0.54	0.25	0.9	0.83	0.35	0.54	0.9	-0.77	0.68	0.7	0.75	0.39	0.8	-0.83	0.82	-0.26	0.89	0.68	0.65		0.48
Other Stockholder Equity	0.76	0.74	0.81	0.48	0.55	-0.93	-0.24	0.66	0.79	0.54	0.92	0.69	-0.53	0.87	0.62	0.31	0.71	0.37	-0.65	0.38	0.28	0.66	0.26	0.31	0.48

Click cells to compare fundamentals

Autolus Therapeutics Account Relationship Matchups

Autolus Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	254.2M	294.2M	405.6M	490.3M	375.4M	279.3M
Other Current Liab	2.3M	496K	150K	40.8M	44.7M	2.2M
Total Current Liabilities	21.1M	33.6M	28.6M	46.4M	44.7M	24.3M
Total Stockholder Equity	232.6M	210.0M	313.3M	298.7M	111.5M	199.4M
Net Tangible Assets	232.6M	209.9M	313.3M	298.7M	267.5M	213.2M
Retained Earnings	(113.3M)	(379.2M)	(521.3M)	(670.2M)	(878.6M)	(119.0M)
Accounts Payable	2.0M	2.3M	431K	531K	103K	1.9M
Cash	217.5M	153.3M	310.3M	382.4M	239.6M	206.2M
Net Receivables	13.3M	29.7M	26.3M	29.0M	24.5M	18.5M
Other Current Assets	105K	43.7M	240K	203K	35.7M	99.8K
Total Liab	21.6M	84.2M	92.2M	191.6M	263.9M	20.5M
Total Current Assets	233.0M	197.0M	347.0M	425.8M	275.3M	231.8M
Intangible Assets	9.3M	254K	158K	65K	58.5K	55.6K
Common Stock	1.3K	2K	3K	4K	8K	3.3K
Property Plant Equipment	20.0M	89.7M	52.3M	58.4M	23.0M	36.1M
Short Long Term Debt Total	54.2M	21.0M	24.3M	53.0M	60.9M	64.0M
Other Liab	601K	492K	47.1M	126.0M	565.8K	537.5K
Property Plant And Equipment Net	89.7M	52.3M	58.4M	95.7M	110.0M	115.5M
Net Debt	(99.1M)	(289.3M)	(358.2M)	(186.6M)	(167.9M)	(176.3M)
Non Current Assets Total	97.3M	58.6M	64.5M	100.1M	115.1M	120.8M
Cash And Short Term Investments	217.5M	153.3M	310.3M	382.4M	239.6M	228.3M
Common Stock Shares Outstanding	51.6M	72.1M	95.0M	173.9M	200.0M	210.0M
Liabilities And Stockholders Equity	294.2M	405.6M	490.3M	375.4M	431.7M	312.1M
Non Current Liabilities Total	50.6M	63.7M	145.2M	219.2M	252.0M	264.6M
Other Stockholder Equity	(15.4M)	595.1M	843.2M	1.0B	1.0B	(14.6M)
Property Plant And Equipment Gross	20.0M	89.7M	75.0M	86.0M	124.4M	19.0M
Accumulated Other Comprehensive Income	(10M)	(5.9M)	(8.6M)	(38.9M)	(29.0M)	(10.5M)
Net Invested Capital	210.0M	313.3M	298.7M	111.5M	128.2M	249.3M
Net Working Capital	163.4M	318.4M	379.4M	230.6M	265.1M	266.4M
Inventory	(29.7M)	10.1M	14.2M	(24.5M)	(22.1M)	(21.0M)
Capital Lease Obligations	54.2M	21.0M	24.3M	53.0M	60.9M	39.3M
Short Term Debt	3.6M	4.5M	5.0M	5.1M	5.8M	4.5M

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Autolus Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

When determining whether Autolus Therapeutics is a strong investment it is important to analyze Autolus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Autolus Therapeutics' future performance. For an informed investment choice regarding Autolus Stock, refer to the following important reports:

How To Invest In Autolus

Details

Is Autolus Stock a good investment?

Details

What is Autolus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.

You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Autolus Stock analysis

When running Autolus Therapeutics' price analysis, check to measure Autolus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Autolus Therapeutics is operating at the current time. Most of Autolus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Autolus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Autolus Therapeutics' price. Additionally, you may evaluate how the addition of Autolus Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Global Correlations Find global opportunities by holding instruments from different markets
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets

Is Autolus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.20)

Revenue Per Share

0.01

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.25)

Return On Equity

(1.02)

The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Autolus Property Plant And Equipment Net vs Retained Earnings Analysis

Property Plant And Equipment Net vs Retained Earnings

Property Plant And Equipment Net vs Retained Earnings Correlation Analysis

Correlation Coefficient

Property Plant And Equipment Net

Retained Earnings

Autolus Therapeutics fundamental ratios Correlations

Autolus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Autolus Therapeutics fundamental ratios Accounts

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Complementary Tools for Autolus Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash
Cash And Short Term Investments	+ 1.0	Cash
Cash And Short Term Investments	+ 1.0	Total Current Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Short Long Term Debt Total

Cash And Short Term Investments	- 0.98	Net Debt
Net Debt	- 0.98	Cash
Net Debt	- 0.97	Total Current Assets
Total Liab	- 0.96	Retained Earnings
Net Debt	- 0.94	Total Assets
Other Stockholder Equity	- 0.93	Retained Earnings